基于尿液的基因组检测改善按美国泌尿外科学会指南分层的高危血尿患者的风险分层
本研究从荷兰前瞻性血尿队列(n=838)中选取尿液DNA生物标志物状态完整的患者,按AUA指南分为低、中、高危组,评估尿液基因组检测对风险分层的改善作用。结果显示所有癌症病例均在高危组(尿路上皮癌发生率16.8%,112/667),诊断模型在各风险组中表现稳健(AUC 0.929-0.971),阴性检测后尿路上皮癌概率为0.3-2%,阳性检测后为31-42%。
要点
- AUA低危且尿液检测阴性的患者,似乎可以安全地暂不进行膀胱镜检查。
- AUA中危或高危且尿液检测阳性的患者,应加快评估。
- 尿液基因组检测可提高AUA指南分层预测尿路上皮癌的准确性。
核心结论
- 本研究表明基于尿液的基因组检测为血尿患者的AUA指南分层增加了价值。
- 对于AUA低危且尿液检测阴性的患者,似乎有理由安全地暂不进行膀胱镜检查。
- 对于AUA中危或高危且尿液检测阳性的患者,应加快评估。
研究设计与样本
- 从先前收集的荷兰前瞻性血尿队列(n=838)中选取尿液DNA生物标志物状态完整的患者。
- 根据性别、年龄和血尿类型将患者分为AUA风险类别。
- 生物标志物状态包括FGFR3、TERT和HRAS基因的突变状态,以及OTX1、ONECUT2和TWIST1基因的甲基化状态。
主要发现
- 总体而言,65例(7.8%)被分类为低危,106例(12.6%)为中危,667例(79.6%)为高危。
- 肉眼血尿组尿路上皮癌发生率为21%(98/457),显微镜血尿组为4%(14/381),两组差异显著(p < 0.001)。
- 所有癌症病例均在高危组,该组尿路上皮癌发生率为16.8%(112/667)。
- 诊断模型在所有风险组中表现稳健(受试者工作特征曲线下面积0.929-0.971)。
- 根据评估的风险组不同,尿液检测阴性对应的检测后尿路上皮癌概率为0.3-2%,而尿液检测阳性对应的检测后尿路上皮癌概率为31-42%。
临床怎么用
- 作者认为,对于AUA低危且尿液检测阴性的患者,似乎有理由安全地暂不进行膀胱镜检查。
- 作者认为,对于AUA中危或高危且尿液检测阳性的患者,应加快评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: According to the recent American Urological Association (AUA) guideline on hematuria, patients are stratified into groups with low, intermediate, and high risk of urothelial carcinoma (UC). These risk groups are based on clinical factors and do not incorporate urine-based tumor markers. OBJECTIVE: To evaluate whether a urine-based genomic assay improves the redefined AUA risk stratification for hematuria. DESIGN, SETTING, AND PARTICIPANTS: We selected patients with complete biomarker status, as assessed on urinary DNA, from a previously collected prospective Dutch hematuria cohort (n = 838). Patients were stratified into the AUA risk categories on the basis of sex, age, and type of hematuria. Biomarker status included mutation status for the FGFR3, TERT, and HRAS genes, and methylation status for the OTX1, ONECUT2, and TWIST1 genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the diagnostic model performance for different hematuria risk groups. Further analyses assessed the pretest and post-test UC probability in the hematuria subgroups using a Fagan nomogram. RESULTS AND LIMITATIONS: Overall, 65 patients (7.8%) were classified as low risk, 106 (12.6%) as intermediate risk, and 667 (79.6%) as high risk. The UC incidence differed significantly between the gross hematuria (21%, 98/457) and microscopic hematuria (4%, 14/381) groups (p < 0.001). All cancer cases were in the high-risk group, which had UC incidence of 16.8% (112/667). Application of the diagnostic model revealed robust performance among all risk groups (area under the receiver operating characteristic curve 0.929-0.971). Depending on the risk group evaluated, a negative urine assay was associated with post-test UC probability of 0.3-2%, whereas a positive urine assay was associated with post-test UC probability of 31-42%. CONCLUSIONS: This study shows the value that a urine-based genomic assay adds to the AUA guideline stratification for patients with hematuria. It seems justified to safely withhold cystoscopy for patients with AUA low risk who have a negative urine assay. In addition, evaluation should be expedited for patients with AUA intermediate or high risk and a positive urine assay. PATIENT SUMMARY: Patients who have blood in their urine (hematuria) can be classified as having low, intermediate, or high risk of having cancer in their urinary tract. We found that use of a urine-based genetic test improves the accuracy of predicting which patients are most likely to have cancer. Patients with a negative test may be able to avoid invasive tests, while further tests could be prioritized for patients with a positive test.
引用
- de Jong JJ, Pijpers OM, van Kessel KEM, et al. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines. Eur Urol Oncol. 2022. PMID: 36089502. doi:10.1016/j.euo.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。